Your browser doesn't support javascript.
loading
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
Morgan, Gregory; Casalino, Selina; Chowdhary, Sunakshi; Frangione, Erika; Fung, Chun Yiu Jordan; Lapadula, Elisa; Arnoldo, Saranya; Bearss, Erin; Binnie, Alexandra; Borgundvaag, Bjug; Briollais, Laurent; Dagher, Marc; Devine, Luke; Friedman, Steven M; Khan, Zeeshan; Mighton, Chloe; Nirmalanathan, Konika; Richardson, David; Stern, Seth; Taher, Ahmed; Wolday, Dawit; Lerner-Ellis, Jordan; Taher, Jennifer.
Afiliação
  • Morgan G; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Casalino S; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Chowdhary S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Frangione E; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Fung CYJ; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Lapadula E; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Arnoldo S; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; William Osler Health System, Brampton, ON L6R 3J7, Canada.
  • Bearss E; Mount Sinai Academic Family Health Team, Mount Sinai Hospital, Toronto, ON M5T 3L9, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada.
  • Binnie A; Department of Critical Care, William Osler Health System, Etobicoke, ON M9V 1R8, Canada.
  • Borgundvaag B; Schwartz/Reisman Emergency Medicine Institute, Sinai Health System, Toronto, ON M5G 2A2, Canada.
  • Briollais L; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada.
  • Dagher M; Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada; Women's College Hospital, Toronto, ON M5S 1B2, Canada.
  • Devine L; Division of General Internal Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Friedman SM; Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada; Emergency Medicine, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Khan Z; Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada.
  • Mighton C; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1A6, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada.
  • Nirmalanathan K; Emergency Medicine, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Richardson D; William Osler Health System, Brampton, ON L6R 3J7, Canada.
  • Stern S; Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada.
  • Taher A; Mackenzie Health, Richmond Hill, ON L4C 4Z3, Canada; Division of Emergency Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.
  • Wolday D; Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada.
  • Lerner-Ellis J; Lunenfeld-Tanenbaum Research Institute, Toronto, ON M5G 1X5, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Taher J; Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: jennifer.taher@sinaihealth.ca.
Vaccine ; 42(11): 2733-2739, 2024 Apr 19.
Article em En | MEDLINE | ID: mdl-38521677
ABSTRACT

BACKGROUND:

GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.

METHODS:

Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.

RESULTS:

Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1-2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.

CONCLUSIONS:

We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article